Thorn-Seshold Lab - Translational Redox Biology

• Since January 2025 Guest Professor at Institute for Clinical Chemistry and Laboratory Medicine
• 2023 – 2024 Subgroup Leader – Biology: Translational chemical biology, Thorn-Seshold Group, Pharmacy Department, LMU Munich
• 2018 – 2023 Scientific and Project Leader: Tumour-selective drug delivery, GO-Bio Project NanoCapture, Pharmacy Department, LMU Munich
• 2015 – 2018 Postdoc: Antiviral immunity, Division of Clinical Pharmacology, University Hospital Munich
• 2010 – 2014 PhD: Pediatric tumour development, Center for Neuropathology, LMU Munich
• 2005 – 2010 Study of Biology at the Universities of Bonn and Munich

Translational Chemical Biology

• Felber, J. G.; Kitowski, A.; Zeisel, L.; Maier, M. S.; Heise, C.; Thorn-Seshold, J.; Thorn-Seshold, O. Cyclic Dichalcogenides Extend the Reach of Bioreductive Prodrugs to Harness Thiol/Disulfide Oxidoreductases: Applications to Seco-Duocarmycins Targeting the Thioredoxin System. ACS Cent. Sci. 2023, https://doi.org/10.1021/acscentsci.2c01465.
• Felber, J. G.; Zeisel, L.; Poczka, L.; Scholzen, K.; Busker, S.; Maier, M. S.; Theisen, U.; Brandstädter, C.; Becker, K.; Arnér, E. S. J.; Thorn-Seshold, J.; Thorn-Seshold, O. Selective, Modular Probes for Thioredoxins Enabled by Rational Tuning of a Unique Disulfide Structure Motif. J. Am. Chem. Soc. 2021, https://doi.org/10.1021/jacs.1c03234.
• Thorn-Seshold, O.; Felber, J.; Thorn-Seshold, J.; Zeisel, L. Disulfide-Based Prodrug Compounds. EP21163944.8, 2021.

Innate Immunity and Tumour Immunology

• Scheck, M. K.; Lehmann, L.; Zaucha, M.; Schwarzlmueller, P.; Huber, K.; Pritsch, M.; Barba-Spaeth, G.; Thorn-Seshold, O.; Krug, A. B.; Endres, S.; Rothenfusser, S.; Thorn-Seshold, J. FluoRNT: A Robust, Efficient Assay for the Detection of Neutralising Antibodies against Yellow Fever Virus 17D. PloS One 2022, https://doi.org/10.1371/journal.pone.0262149.
• Ruzicka, M.; Koenig, L. M.; Formisano, S.; Boehmer, D. F. R.; Vick, B.; Heuer, E.-M.; Meinl, H.; Kocheise, L.; Zeitlhöfler, M.; Ahlfeld, J.; Kobold, S.; Endres, S.; Subklewe, M.; Duewell, P.; Schnurr, M.; Jeremias, I.; Lichtenegger, F. S.; Rothenfusser, S. RIG-I-Based Immunotherapy Enhances Survival in Preclinical AML Models and Sensitizes AML Cells to Checkpoint Blockade. Leukemia 2020, https://doi.org/10.1038/s41375-019-0639-x.

Tumour Development

• Ahlfeld, J.; Filser, S.; Schmidt, F.; Wefers, A. K.; Merk, D. J.; Glaß, R.; Herms, J.; Schüller, U. Neurogenesis from Sox2 Expressing Cells in the Adult Cerebellar Cortex. Sci. Rep. 2017,https://doi.org/10.1038/s41598-017-06150-x.
• Ahlfeld, J.; Favaro, R.; Pagella, P.; Kretzschmar, H. A.; Nicolis, S.; Schüller, U. Sox2 Requirement in Sonic Hedgehog-Associated Medulloblastoma. Cancer Res. 2013, https://doi.org/10.1158/0008-5472.CAN-13-0238